Literature DB >> 12137410

BIBR-1048 Boehringer Ingelheim.

Dennis Mungall1.   

Abstract

BIBR-1048, a thrombin inhibitor and an orally-active prodrug of BIBR-953ZW, is under development by Boehringer Ingelheim as a potential antithrombotic agent [331881]. By 1999, BIBR-1048 was in phase II clinical trials for thromboembolism and the prevention of stroke due to atrial fibrillation [331881]; by April 2002, proof-of-principle had been demonstrated in phase II trials in deep vein thrombosis [446554]. In July 2001, the company revealed that an IND was expected to be filed for BIBR-953ZW in 2002 [415884].

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12137410

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  10 in total

1.  New direct thrombin inhibitors.

Authors:  Alessandro Squizzato; Francesco Dentali; Luigi Steidl; Walter Ageno
Journal:  Intern Emerg Med       Date:  2009-09-15       Impact factor: 3.397

2.  Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice.

Authors:  Kun Shi; Helene Damhofer; Joost Daalhuisen; Marieke Ten Brink; Dick J Richel; C Arnold Spek
Journal:  Mol Med       Date:  2017-02-06       Impact factor: 6.354

Review 3.  Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery.

Authors:  Bengt I Eriksson; Daniel J Quinlan
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.

Authors:  Bengt I Eriksson; Daniel J Quinlan; Jeffrey I Weitz
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  New developments in anticoagulation for atrial fibrillation.

Authors:  M Haris U Usman; Lawrence A Notaro; Harsh Patel; Michael D Ezekowitz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-09

Review 6.  Advancement in antithrombotics for stroke prevention in atrial fibrillation.

Authors:  Mohammed Haris Umer Usman; Sabreen Raza; Shariq Raza; Michael Ezekowitz
Journal:  J Interv Card Electrophysiol       Date:  2008-04-17       Impact factor: 1.900

Review 7.  Stroke prevention: modifying risk factors.

Authors:  José Rafael Romero; Jane Morris; Aleksandra Pikula
Journal:  Ther Adv Cardiovasc Dis       Date:  2008-08

8.  Translatability scoring in drug development: eight case studies.

Authors:  Alexandra Wendler; Martin Wehling
Journal:  J Transl Med       Date:  2012-03-07       Impact factor: 5.531

Review 9.  Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.

Authors:  Antonio Gómez-Outes; M Luisa Suárez-Gea; Ramón Lecumberri; Ana Isabel Terleira-Fernández; Emilio Vargas-Castrillón
Journal:  Vasc Health Risk Manag       Date:  2014-11-07

Review 10.  Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.

Authors:  Antonio Gómez-Outes; M Luisa Suárez-Gea; Ramón Lecumberri; Ana Isabel Terleira-Fernández; Emilio Vargas-Castrillón; Eduardo Rocha
Journal:  Vasc Health Risk Manag       Date:  2013-05-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.